Reactivity to P-Glycoprotein, P53 and MDM2 in Dogs Affected with Multicentric Lymphoma
Introduction
Drug resistance is associated with cellular mechanisms and factors that affect the bioavailability and efficacy of drugs. One of the most studied mechanisms are the overexpression of P-gp, p53 gene and MDM2 oncogene.
Objectives
Correlating at diagnosis immunophenotyping with the expression of P-gp, MDM2 and p53, by immunohistochemistry in lymph nodes of dogs with lymphoma.
Methodology
Twenty dogs with multicentric lymphoma treated in the Veterinary Hospital - UNESP/Jaboticabal were studied. Antibodies to p53 (CM1 clone), MDM2 (ab38618 clone) and P-gp (C494 clone) were used.
Results
Nuclear positive immunostaining of p53 was observed in 25% (5/20) of the samples, while 75% (15/20) were negative. Regarding reactivity of MDM2, it was possible to identify nuclear and cytoplasmatic immunostaining in 30% (6/20) of the samples, while 70% (17/20) were negative. Patients expressing both markers (p53 and MDM2) had a shorter survival rate (p<0.05). When evaluating the expression of P-gp, it was possible to identify positive cytoplasmatic immunostaining in 80% (16/20) of the samples, and only 20% (4/20) were negative. It was not possible to identify significant difference in the survival curve (p=0.5238).
Conclusion
Patients who simultaneously expressed P53 and MDM2 had a lower survival rate. p53 and MDM2 activity during neoplastic processes negatively affects the treatment and prognosis of animals affected by lymphoma. P-gp expression had no difference in the survival of patients.